Overview: Hematologic Malignancy Chromosome (Heme Chromosome) TestIntroduction: The Hematologic Malignancy Chromosome Test analyzes chromosomes to diagnose blood cancers like leukemia, causing fatigue or bruising. Aligned with 2023 ASH guidelines, it uses microscopy for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in cytogenetics for patients with suspected blood cancers.
Other Names: Chromosome Analysis Assay, Leukemia Cytogenetic Test.
FDA Status: Laboratory-developed test (LDT), meeting cytogenetics standards for diagnostic accuracy.
Historical Milestone: Chromosome analysis for blood cancers began in the 1960s with leukemia research. Microscopy-based karyotyping emerged in the 1970s, and by the 2000s, advanced techniques improved diagnostic accuracy.
Purpose: Diagnoses blood cancers, guides treatment, and monitors chromosomal abnormalities in patients with fatigue or bruising.
Test Parameters: 1. Chromosome Analysis
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or bruising, and list medications like chemotherapy.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bruising, or family history of blood cancers. Include current medications, especially chemotherapy or targeted therapies.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for leukemia treatment.
Procedural Considerations: Uses microscopy for karyotyping to detect chromosomal abnormalities. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low sample quality or improper storage can reduce sensitivity. Recent chemotherapy may affect results.
Clinical Significance: Chromosomal abnormalities confirm blood cancers, prompting chemotherapy or transplant. Normal results may require molecular testing.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: FISH testing, flow cytometry, or bone marrow biopsy to confirm blood cancers or assess disease extent.
Test Limitations: False negatives may occur with low cell counts. Results require clinical correlation with molecular tests.
References: ASH Leukemia Guidelines, 2023; Blood, Döhner H, 2022.
